Therefore, under WTP thresholds of $150,000/QALY in the U.S. and $40,334/QALY in China, the inavolisib triple regimen was not economically viable as first-line therapy for advanced HR+/HER2- breast cancer patients with PIK3CA mutations in both countries. This evidence concerns the gene PIK3CA and breast carcinoma.